Revolution Medicines
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cance...
Latest News
12 hours ago · globenewswire.com
European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerREDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Commission (EC) has approved RASONQUE (daraxonrasib) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.1 RASONQUE, given once daily as oral tablets, is approved for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.
16 hours ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 TranscriptRevolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4 days ago · seekingalpha.com
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are HighRevolution Medicines has transitioned to commercial operations with a strong initial RASONQUE launch, generating $197.6M in five weeks post-FDA approval. RASONQUE's early demand is validated by over 5,000 unique U.S. patients and broad reimbursement, but initial revenues include non-recurring factors and should not be annualized. RVMD's valuation is demanding at 63x forward sales, reflecting high expectations for RASONQUE's expansion and pipeline execution, leaving little room for operational missteps.
6 days ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference TranscriptRevolution Medicines, Inc. ( RVMD ) 3rd Annual Guggenheim Healthcare Innovation Conference November 10, 2026 8:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Presentation Unknown Analyst Kick off this next discussion with Revolution Medicines. With me today, I have Mark Goldsmith, CEO.
6 days ago · zacks.com
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a BetThe consensus price target hints at a 33.3% upside potential for Revolution Medicines (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
9 days ago · fool.com
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?Its lead therapy is approved to treat previously treated patients with an advanced form of pancreatic cancer. The young drug company has a revolutionary pipeline of RAS-inhibitor therapies.
11 days ago · seekingalpha.com
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows ItRevolution Medicines delivered $198M in Q3 revenue from RASONQUE's five-week U.S. launch, treating over 5,000 patients post-FDA approval. Despite strong early sales, RVMD's $40B valuation and high expectations temper further upside until sustained commercial traction or pivotal readouts materialize. RASONQUE's clinical data show clear superiority over chemotherapy in pancreatic cancer; expansion into NSCLC and other solid tumors underpins RVMD's multi-asset pipeline thesis.
11 days ago · zacks.com
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque UptakeRevolution Medicines' Q3 revenues beat estimates as Rasonque generated $197.6 million in just five weeks, signaling strong early launch demand.
12 days ago · marketbeat.com
What Revolution Medicines (RVMD) Said on Its Q3 Earnings CallRevolution Medicines NASDAQ: RVMD reported $197.6 million in third-quarter net product revenue from its newly approved pancreatic cancer treatment RASONQUE, reflecting roughly five weeks of U.S. sales and treatment of more than 5,000 commercial patients.
12 days ago · seekingalpha.com
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call TranscriptRevolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RVMD